GLP-2 Peptides Explained: Teduglutide, Glepaglutide & Intestinal Regrowth

The explosion of interest in GLP-1 receptor agonists for weight loss has created a common point of confusion: many people assume GLP-2 is simply a newer or stronger version of the same thing. It is not. Glucagon-like peptide-2 comes from the same parent molecule as GLP-1 — both are cleaved from proglucagon in the intestine — but it acts on a different receptor and produces a fundamentally different biological effect. Where GLP-1 influences appetite, insulin, and gastric emptying, GLP-2's signature action is on the structure of the gut lining itself.

How GLP-2 Differs From GLP-1

GLP-1 and GLP-2 are secreted together from the same enteroendocrine L-cells in response to food. Despite sharing a source, they diverge sharply in function.

GLP-1 is best known for enhancing glucose-dependent insulin secretion, slowing gastric emptying, and reducing appetite through central pathways. These are the properties that made drugs like semaglutide and tirzepatide central to modern metabolic medicine.

GLP-2 binds a distinct receptor (GLP-2R) expressed mainly in the gut, and its defining property is described as intestinotrophic — meaning it stimulates growth of the intestinal lining. It does not meaningfully influence blood glucose or appetite. In practical terms, GLP-2 is a gut-repair signal, not a metabolic-appetite signal.

The Intestinotrophic Mechanism

The small intestine absorbs nutrients across a vast surface area created by finger-like villi and their microscopic microvilli. GLP-2 supports and expands this absorptive machinery through several described actions:

• Mucosal growth. GLP-2 promotes proliferation of crypt cells and reduces cell death in the villi, which can increase villus height and overall mucosal mass. A taller, denser lining has more surface area to absorb nutrients and water.
• Blood flow. GLP-2 increases mesenteric (intestinal) blood flow, supporting nutrient delivery and the metabolic demands of a growing mucosa.
• Barrier function. By supporting epithelial integrity and tight-junction behavior, GLP-2 is associated with a less permeable, more intact gut barrier.
• Reduced motility and secretion. GLP-2 can slow transit and reduce gastric secretion, giving the gut more time to absorb what passes through.

Interestingly, GLP-2 receptors are not located directly on the absorptive enterocytes that do most of the growing. The signal appears to work indirectly through intermediary cells that release downstream growth factors — one reason the biology is still being mapped in detail.

Why This Matters: Short Bowel Syndrome

The clearest medical application of GLP-2 biology is short bowel syndrome (SBS). SBS occurs when a large portion of the small intestine has been surgically removed or is non-functional — often after Crohn's disease complications, vascular events, or trauma. With too little absorptive surface remaining, patients may be unable to maintain hydration and nutrition through eating alone.

Many people with severe SBS depend on parenteral support — intravenous nutrition and fluids, often for many hours each day. This is life-sustaining but burdensome and carries risks such as line infections and liver complications. The therapeutic goal of GLP-2 analogs is to enhance the absorptive capacity of the remaining bowel enough to reduce that dependence.

Teduglutide: The FDA-Approved Analog

Native GLP-2 is broken down within minutes by the enzyme DPP-4, making the natural peptide impractical as a drug. Teduglutide (brand name Gattex in the US, Revestive in some regions) is an analog engineered with a single amino acid substitution that resists DPP-4 degradation, extending its activity long enough to be dosed once daily by subcutaneous injection.

Teduglutide is approved for adults and pediatric patients with short bowel syndrome who are dependent on parenteral support. In clinical use, the objective is a meaningful reduction in the volume of intravenous fluid and nutrition required — some patients achieve substantial reductions, and a subset can reduce their number of infusion days per week. Responses vary by individual and by how much functional bowel remains.

Its approval status is the key distinction to hold onto: teduglutide is a prescription medicine used under specialist supervision, not a research-only or wellness peptide.

Glepaglutide: The Investigational Weekly Option

Glepaglutide is a longer-acting GLP-2 analog studied as a potential lower-frequency alternative. Its design aims for a longer duration of action than teduglutide, with dosing schedules investigated in the range of once or twice weekly rather than daily — a meaningful quality-of-life difference for people managing a chronic condition with daily injections.

As of mid-2026, glepaglutide should be understood as investigational: its role is being defined through clinical development rather than routine practice, and where it is available it is within trial or regulatory-review contexts depending on region. It represents the same therapeutic logic as teduglutide with a convenience-oriented profile, not a proven superior outcome.

Monitoring and Polyp Surveillance

Because GLP-2 analogs stimulate cell growth in the gut, safety monitoring centers on that same property. The growth-promoting effect that helps damaged bowel is also a reason for caution about tissue that should not grow.

• Colorectal surveillance. Prescribing guidance for teduglutide includes colonoscopy to evaluate for polyps before starting therapy and periodic surveillance thereafter, because a growth-promoting agent could theoretically accelerate existing neoplastic tissue. Any polyps found are typically removed, and active gastrointestinal malignancy is a contraindication.
• Fluid and electrolyte balance. Improved absorption can shift fluid status; clinicians adjust parenteral support to avoid overload and monitor electrolytes.
• Biliary and pancreatic monitoring. GLP-2 effects on gallbladder and pancreatic tissue mean symptoms in those areas are evaluated during treatment.
• Intestinal obstruction and stoma changes. Enhanced mucosal growth can occasionally narrow the bowel or a stoma opening, which requires assessment.

This monitoring framework is a core reason GLP-2 therapy belongs in specialist hands rather than self-directed use.

Where BPC-157, VIP, and Larazotide Fit

Interest in gut-repair peptides extends well beyond the approved GLP-2 analogs, though the evidence base thins considerably outside them.

BPC-157 is a gastric peptide studied extensively in animal models of gastrointestinal injury, where it shows effects on mucosal healing and angiogenesis. Its human evidence remains very limited, and it acts through different pathways than GLP-2 rather than being a substitute for it.

VIP (vasoactive intestinal peptide) is a signaling molecule with roles in gut motility, secretion, and immune regulation. It is a subject of research interest rather than an established gut-regrowth therapy.

Larazotide takes a different angle entirely — instead of promoting growth, it has been investigated as a tight-junction regulator intended to reduce intestinal permeability, most notably in the context of celiac disease. It is an experimental agent aimed at barrier function, not mucosal expansion.

These compounds are frequently discussed alongside GLP-2 because they touch gut health, but they occupy separate and much less mature evidence categories.

The Bottom Line

GLP-2 is not a variant of the weight-loss GLP-1 peptides — it is a distinct signal whose job is to grow and repair the intestinal lining. That intestinotrophic action has produced a genuine, approved therapy: teduglutide for short bowel syndrome, used to reduce dependence on intravenous nutrition. Glepaglutide extends the same idea toward less frequent dosing but remains investigational.

The same growth-promoting mechanism that makes GLP-2 useful is why it demands structured monitoring, including polyp surveillance. This is specialist territory. Anyone with a serious gut condition should pursue GLP-2 therapy through a knowledgeable clinician rather than as a self-managed experiment, and should treat the wider field of gut peptides — BPC-157, VIP, larazotide — as areas of active research rather than settled medicine.